Windlas Biotech Ltd

Windlas Biotech Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of early February 2026. This change reflects evolving market perceptions amid a competitive pharmaceutical and biotechnology sector, with key valuation multiples such as price-to-earnings (P/E) and price-to-book value (P/BV) adjusting relative to historical averages and peer benchmarks.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Windlas Biotech Ltd’s shares declined sharply to a new 52-week low of Rs.708.9 on 9 Mar 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock has underperformed its sector and the broader market over the past year, reflecting subdued financial results and valuation pressures.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing downside pressure amid a challenging market environment for the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a downgrade in its overall Mojo Grade to Sell. This change reflects evolving market perceptions amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling entry point relative to peers and historical averages.

Windlas Biotech Ltd has experienced a subtle but noteworthy shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators reveal a nuanced picture that investors should carefully analyse amid broader market volatility.

Windlas Biotech Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 4 February 2026. The stock’s recent price action and technical indicators suggest a bearish trend, with the share price declining 1.92% on 5 March 2026 to close at ₹740.00, down from the previous close of ₹754.45.

Windlas Biotech Ltd’s shares declined to a fresh 52-week low of Rs.728.15 on 4 March 2026, marking a significant price level for the pharmaceutical and biotechnology company amid a series of recent setbacks and subdued market performance.

Windlas Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.728.15 today, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and the broader market over the past year, reflecting a challenging period for the company’s share price.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory, despite recent share price softness and sector headwinds. This recalibration in price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical averages and peer benchmarks offers investors a compelling case to reassess the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Windlas Biotech Ltd experienced a significant intraday decline on 11 Feb 2026, touching a low of Rs 782, down 8.11% from its previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and subdued market sentiment within the Pharmaceuticals & Biotechnology space.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance, as reflected in recent indicator signals. Despite a modest day gain of 1.82%, the company’s technical parameters present a complex picture with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a downgrade in its Mojo Grade from Hold to Sell on 4 February 2026.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent upgrade in price, the stock remains under pressure from mixed monthly technicals and a downgraded Mojo Grade, signalling caution for investors navigating the Pharmaceuticals & Biotechnology sector.